Where does Axon Therapies, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Axon Therapies, Inc. ranks #18,414 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Axon Therapies, Inc. hold?

Axon Therapies, Inc. holds 15 US utility patents granted between 2019 and 2025, spanning 4 technology areas.

What is Axon Therapies, Inc.'s Innovation Score?

Axon Therapies, Inc. has an Innovation Score of 39.5 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Axon Therapies, Inc. focus on?

Axon Therapies, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 15 patents, ranking #1,165 of 7,127 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Axon Therapies, Inc.'s patent grant rate increasing or decreasing?

Axon Therapies, Inc.'s recent grant velocity is +500% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Axon Therapies, Inc.'s patents?

Axon Therapies, Inc.'s patents average 18.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Axon Therapies, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Axon Therapies, Inc.

USPTO PatentsView assignee record - 15 granted patents across 4 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Axon ranks #18,414 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 4 technology areas.

#18,414
of 49,997 US assignees by volume: Top 38%
by Innovation Score (39.5/100): 18.0
avg claims per patent: +500%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18414 · US Corporation #18,414 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,414/49,997
PHOTO-FINISH AbbVie S á r l
CPC-NARROW A61B · 4 areas
INNOV-THIN 39.5/100
CLAIMS-RICH 18.0 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +500% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: AbbVie S.á.r.l. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Axon’s 39.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (24%) Velocity 12.0 pts (30%) Breadth 7.1 pts (18%) Claim depth 10.8 pts (27%)

Qualcomm Incorporated · highest

85
Axon Therapies · this assignee

39
3D Lighting… · lowest

7

What this shows Axon's Innovation Score is 39.5/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Axon?

Each dot is one of Axon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Axon’s own 18.0 claims/patent is at or below the 20.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Axon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Axon's grants concentrate

Axon Therapies, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2023 (5 grants) versus a trough of 1 in 2020. By volume, Axon sits between Attostat, Inc. and AbbVie S.á.r.l..

Axon's three-year grant acceleration

Axon Therapies, Inc. shows 9 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Attostat

15
AU Optronics (Suz…

15
Avient Protective…

15
AVK Holding A/S

15
Ayrton

15
Azotek

15
Abvitro

15
Abbvie S á r l

15
Axon Therapies ◀

15

What this shows Axon holds 15 patents at rank #18,374, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Axon

By rank, the assignees closest to #18,374 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Axon's primary technology class.

Axon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 38% higher than 62% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Axon Therapies, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	13.3%
2020	1	6.7%
2021	2	13.3%
2022	3	20.0%
2023	5	33.3%
2024	1	6.7%
2025partial year	1	6.7%

Which technologies does Axon Therapies, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 15

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 13

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 6

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Axon Therapies, Inc.'s patent record in context - here's where to go next.

Axon Therapies, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #18,414 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Axon Therapies, Inc. against Attostat, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.